Acceleron Pharma, Inc.
http://acceleronpharma.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acceleron Pharma, Inc.
Acceleron To Be Next M&A Target With Rumored $11bn Deal
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.
Are Biotech Investors Still Being Led By Science Fundamentals?
From the Aduhelm approval to exuberant stock markets, life sciences investor and In Vivo Rising Leader John Cassidy shares insights into industry trends, highlighting areas where decisions may have moved away from scientific fundamentals.
Fulcrum’s Losmapimod Improves Multiple Measures, But Not Primary Endpoint
The ReDUX4 study missed its biomarker-driven primary endpoint, making it unclear if an additional trial will be needed for regulatory submission.
BMS's Reblozyl Data Supports Adding Less Severe Patients To Label
Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule